First FDA Approved Medication for Agitation Associated with Alzheimer’s Dementia
On May 11, 2023: FDA announced the approval of Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the…
On May 11, 2023: FDA announced the approval of Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the…
Today FDA has approved the first sublingual medication, IGALMI (Dexmedetomidine) for the management of acute agitation in indications discussed below. We have summarized this medication…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.